Wayne Rothbaum
About Wayne Rothbaum
Wayne Rothbaum, who founded investment firm Quogue Capital in 2001, became a wildly successful biotech investor, deploying only his own funds.
In 2012, Rothbaum cofounded and became the largest investor in cancer drug developer Acerta Pharma, whose drug Calquence was approved to treat forms of lymphoma and leukemia.
In 2016, AstraZeneca paid $4 billion for 55% of Acerta Pharma and agreed to acquire the remainder of Acerta for nearly $2.5 billion paid between 2022 and 2024.
Rothbaum is executive chair of two cancer drug firms: Kartos Therapeutics, which he cofounded in 2016, and Telios Pharma, cofounded in 2019.
Rothbaum also led a restructuring of listed biotech firm Iovance Biotherapeutics, where he is a board member and the largest shareholder, with a stake of more than 10%.
Personal stats
Citizenship
United States of AmericaSource of wealth
Biotech investingResidence
Delray Beach, FloridaMarital status
MarriedBirth date
02/17/68 (age 56)Number of children
3Education
Master of Arts, George Washington University; Bachelor of Arts/Science, State University of New York at BinghamtonSelf-made
self-madeWayne Rothbaum’s fortune is worth
troy ounces of gold
median U.S. household
median U.S. income
U.S. credit card volume
GDP of the United States
United States debt
Net worth history
Annual ranking
Did you know?
Rothbaum donated $300 million to SUNY Binghamton--for a sports complex and scholarships--and to Ohio State University to build housing for cancer patients.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | IOVA-US
Iovance BiotherNASDAQ | IOVA-US
Iovance BiotherImages © Forbes.com. All rights reserved.